pillbase.ru

Imlygic

Active substance: talimogene laherparepvec

INJECTION, SUSPENSION · TALIMOGENE LAHERPAREPVEC 100000000 [PFU]/mL

United StatesActive

Marketing holder: Amgen Inc

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 1
  • Imlygic
    talimogene laherparepvec
    EMEA/H/C/002771
    Amgen Europe B.V.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208f-ed4c-7eae-b1cb-31e967647357,01a12098-d02f-786e-ba00-9754907bc8d4;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
55513-079
Registration status
Active
Dispensing
Prescription only
Route
INTRALESIONAL
Sources
  • product · openFDA NDC · 55513-079 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 55513-079 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 55513-079 · Verified 2026-10-09 · open in source